Intellia Therapeutics, Inc. Reports Results For The Quarter Ended June 30: Earnings Summary

INTELLIA THERAPEUTICS

06/08/2026 14:32

INTELLIA THERAPEUTICS, INC. NTLA.OQ reported a quarterly adjusted loss of 80 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -98 cents.  The mean expectation of sixteen analysts for the quarter was for a loss of 80 cents per share. Wall Street expected results to range from -95 cents to -63 cents per share.
Revenue fell 46.2% to $7.66 million from a year ago; analysts expected $13.90 million. 
INTELLIA THERAPEUTICS, INC.'s reported EPS for the quarter was a loss of 80 cents​.
The company reported a quarterly loss of $106.63 million.
INTELLIA THERAPEUTICS, INC. shares had fallen by 35.2% this quarter and gained 22.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 10.2% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 8 "strong buy" or "buy," 7 "hold" and 3 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."
Wall Street's median 12-month price target for INTELLIA THERAPEUTICS, INC. is $17.00, about 35.5% above its last closing price of $10.97
This summary was machine generated from LSEG data August 6 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.80
-0.80
Met
Mar. 31 2026 
-0.91
-0.81
Beat
Dec. 31 2025 
-0.95
-0.83
Beat
Sep. 30 2025 
-1.00
-0.92
Beat